Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07362056

Implementing Suicide Prevention Into Primary Care in Nepal

Suicide remains a major contributor to global mortality, with particularly high and persistent rates in low-resourced settings such as South Asia. In Nepal, ongoing integration of mental health services into primary care provides a critical opportunity to strengthen suicide risk assessment and management. Despite the scale-up of mhGAP training for primary care providers (PCPs), gaps remain in the systematic detection, referral, and follow-up of individuals at risk for suicide. There is an urgent need to enhance mhGAP implementation with strategies that address provider workload, stigma, and inequities within the health workforce.

Using experience-based co-design principles and RE-AIM this study will assess the feasibility and acceptability of integrating an implementation strategy package to optimize mhGAP suicide prevention delivery in Nepal's decentralized primary healthcare system. This clinical trial leverages deep collaboration with a community advisory board of individuals with lived experience of suicide throughout the trials' design, delivery and analysis.

This R34 will generate critical preliminary evidence on the feasibility, acceptability, and implementation of an integrated suicide prevention package within government primary care facilities in Nepal. The findings will inform the design and parameters of a future fully powered effectiveness trial, while aligning with Nepal's national suicide prevention strategy and advancing WHO and NIMH global mental health priorities.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Primary care facilities

Dolakhā, Nepal

Location status: Recruiting

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Primary Care Providers

  • Health workers with a prescribing license employed in government health facilities in Bagmati Province.
  • Are between 21-65 years, per government health system criteria.
  • Participants will be required to have competency in Nepali, be actively engaged in care provision within their health facility

Patients:

  • Patient lives in the study site
  • Is under the care of a PCP at a facility site.
  • Patient meets any level of suicide risk based on mhGAP 2.0 criteria.
  • Patients who have been treated for mental illness before or presently (expected in both groups).
  • Speaks Nepali.
  • Levels of Suicide Risk (as defined by mhGAP 2.0)

Exclusion criteria

Primary Care Providers

  • Healthcare workers without proper government credentials will be excluded.
  • Health workers who plan to migrate or who do not intend to stay in the study area for at least a year.

Patients:

  • Patient requiring immediate hospitalization
  • Unable to consent as determined by the diminished capacity tool.

Treatment and study plan

Suicide Prevention Package (PSuPP)

Behavioral

Implementation package to optimize mhGAP siucide prevention delivery which includes: [assessment optimization] systematic assessment training using systematized screening questions, an embedded decision-support tool, [risk management optimization] culturally adapted safety planning, and [follow up care optimization] a collaborative care protocol with CHWs to support patient follow-up uptake and continued care.

Primary outcomes

  1. Percent intervention arm uptake to assess feasibility

    Time frame: 6 months

    Percent primary care providers (PCPs) that attend the implementation training. Feasibility will be defined as 70% or more uptake.

  2. Percentage of interviews that hold themes

    Time frame: 6 months

    Qualitative feasibility acceptability data will be deemed acceptable if it demonstrates provider and patient perceptions of P-SuPP benefits to clinical care and mhGAP implementation and the absence of themes that suggest -SuPP is disruptive, unlikeable, and unacceptable. Acceptability will be assessed as the percentage of interviews that hold themes suggesting SuPP is disruptive, unlikeable, and unacceptable.

  3. Percent retention to assess feasibility

    Time frame: 6 months

    Percent participants enrolled (PCPs and Patients) who complete the study of all enrolled. Feasibility is established as retention of at least 65% completion of 6 month follow up of patients and PCPs.

  4. Structured checklist to assess fidelity

    Time frame: 6 months

    18-item structured checklist assessed in a standardized behavioral rehearsal to assess fidelity to the mhGAP suicide module protocol

  5. Percent successful allocation procedures

    Time frame: 6 months

    Percent successful allocation procedures followed

  6. Percent adherence to the randomization protocol

    Time frame: 6 months

    Percent adherence to the randomization protocol

  7. Percent deviations to the randomization protocol

    Time frame: 6 months

    Percent deviations to the randomization protocol

  8. Percent participants who completed all follow up measures

    Time frame: 6 months

    Percent participants who completed all follow up measures

  9. Percent missing measure items per participant

    Time frame: 6 months

    Percent missing measure items per participant

  10. Mean Beck Scale for Suicide Ideation (BSSI) score

    Time frame: Baseline; 3 months; 6 months

    Suicide ideation severity measured with BSSI. BSSI is a 19-item self-report instrument for detecting and measuring the current intensity of the patients' specific attitudes, behaviors, and plans to commit suicide during the past week. The first 19 items consist of three options graded are on a 3-point scale ranging from 0 to 2. These items are then summed to yield a total score, which ranges from 0 to 36. Higher scores indicate higher severity of suicide ideation. Assessed in patients only.

Secondary outcomes

  1. Suicide Prevention Knowledge survey

    Time frame: Baseline, 3 months; 6 months

    The mhGAP knowledge survey includes 9 items related to suicide specific knowledge related to suicide risk presentation, management, and carer engagement aligned with the mhGAP suicide prevention protocol. Total score range XXXXX. Higher scores indicate more knowledge. Assessed in PCPs only.

  2. Mean Self-Efficacy in Mental Health Care survey score

    Time frame: Baseline; 3 month; 6 month

    The mhGAP Self Efficacy is a self-administered measure assessing healthcare providers' confidence in assessing, diagnosing, and managing mental health conditions. Our adapted tool has 45 items across all domains and 8 items that focus specifically on suicide. Respondents select a range of responses between 1 and 5 with 1 feeling totally unable to do the domain and 5 feeling totally able to do the domain. Higher scores indicate higher self-efficacy. Assessed in PCPs only.

  3. Mean Clinical Competency and Communication Skills (ENACT) score

    Time frame: Baseline; 6 months

    This is an observed role play with a trained rater to assess competence and interpersonal skills in delivering mental health interventions. The tool evaluates core competencies in psychological care delivery including: Communication, Emotional Engagement, Assessment, Social Relations, Planning and Process. communication skills, empathy, active listening, and patient engagement. Total score range 0-3. Higher scores indicate higher competence. Assessed in PCPs only.

  4. Columbia Suicide Severity Rating Scale

    Time frame: Baseline; 3 months; 6 months

    The CSSRS asks about self-reported suicide attempt, aborted attempt, preparatory behavior, and interrupted attempt with "yes" or "no" questions branching format. Any positive responses to these behaviors will be coded as 'yes'. Behaviors are assessed at baseline as the past 3 months and lifetime and subsequent assessments have a window of the past three months. Participants will be categorized as low, medium or high risk based on their answers to specific questions. Assessed in patients only.

  5. Mean Patient Health Questionnaire (PHQ-9) score

    Time frame: Baseline; 3 months; 6 months

    Depression measured with PHQ-9. PHQ-9 is a 9-item validated questionnaire. Each item asks about the frequency of specific depressive symptoms experienced over the past two weeks. The response options are scored from 0 to 3, indicating "not at all" to "nearly every day." The item scores are summed with total score on the PHQ-9 ranges from 0 to 27, with higher scores indicating greater severity of depressive symptoms.

  6. Mean Suicide Cognitions Scale (SCS) score

    Time frame: Baseline; 3 months; 6 months

    The SCS includes 21 items that assess suicide-related cognitions, including negative expectations about the future, maladaptive self-perceptions, and emotional pain. The scale asks respondents to rate the extent to which they agree with experience specific suicide-related thoughts and beliefs. Responses are recorded on a Likert-type scale ranging from 1 to 5 from strongly disagree to strongly agree, and item scores are summed to produce a total score (21-105), with higher scores indicating greater severity of suicide-related cognitive distress. Assessed in patients only.

  7. Suicide-Related Coping Scale (SRCS) - Internal Coping Skills

    Time frame: Baseline; 3 months; 6 months

    Assess suicide-related internal coping skills (7 items on 5-point scales; scores range from 0 to 28 with higher scores indicating better internal coping). Assessed in patients only.

  8. Suicide-Related Coping Scale (SRCS) - External Coping Skills

    Time frame: Baseline; 3 months; 6 months

    Assess suicide-related internal coping skills (7 items on 5-point scales; scores range from 0 to 28 with higher scores indicating better external coping). Assessed in patients only.

  9. Mean Generalized Anxiety Disorder (GAD-7) score

    Time frame: Baseline; 3 months; 6 months

    Anxiety measured with GAD-7, a 7 item self report instrument that measures anxiety Items are scored on a 4-point scale, ranging from "not at all (0)" to "nearly everyday (3)". Item scores are summed with a total score ranging from 0 to 21: 0-4 Minimal anxiety; 5-9 Mild anxiety; 10-14 Moderate anxiety; 15-21 Severe anxiety. Assessed in patients only.

  10. Mean Social Connectedness Scale score

    Time frame: Baseline; 3 months; 6 months

    The Social Connectedness Scale consists of 8 items that assess perceived sense of closeness, belonging, and connection with others. The scale consists of multiple items that ask respondents to rate their agreement on a scale of 1 to 5, with 1 indicating strong disagreement and 5 indicating strong agreement. Higher scores indicate higher social connection. Assessed in patients only.

  11. Client Service Receipt Inventory to assess health service uptake

    Time frame: Baseline; 3 months; 6 months

    Percent services utilized will be assessed using the Client Services Receipt Inventory which measures use of health and social care services ranging from community delivered care from community health workers, to primary care services, to specialist services, and traditional health services. Assessed in patients only.

Study contacts

Contact information is provided by the study sponsor or research team.

Ashley K Hagaman, PhD, MPH

CONTACT

[email protected]

2487908954

Sponsors and collaborators

Lead sponsor

Yale University

Other

Collaborators

  • National Institute of Mental Health (NIMH)
  • Possible

Registry information

Official study title

Integrating a Suicide Prevention Package of Strategies Into Decentralized Primary Health Care Systems: an Implementation Pilot Study in Rural Nepal

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Jan 23, 2026
Registry last updated
Jan 23, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.